Identification and Profiling of a Novel Diazaspiro[3.4]octane Chemical Series Active against Multiple Stages of the Human Malaria Parasite Plasmodium falciparum and Optimization Efforts.
Claire Le ManachJean DamJohn G WoodlandGurminder KaurLutete P KhondeChristel BrunschwigMathew NjorogeKathryn J WichtAndré HoratscheckTanya PaquetGrant A BoyleLiezl GibhardDale TaylorNina LawrenceTomas YeoSachel MokRichard T EastmanDorjbal DorjsurenDaniel C TalleyHui GuoAnton SimeonovJanette ReaderMariëtte van der WattErica ErlankNelius VenterJacek W ZawadaAyesha AswatLuisa NardiniTheresa L CoetzerSonja B LauterbachBelinda C BezuidenhoutAnjo TheronDalu MancamaLizette L KoekemoerLyn-Marie BirkholtzSergio WittlinMichael DelvesSabine OttilieElizabeth A WinzelerThomas W von GeldernDennis SmithDavid A FidockLeslie J StreetGregory S BasarabJames DuffyKelly ChibalePublished in: Journal of medicinal chemistry (2021)
A novel diazaspiro[3.4]octane series was identified from a Plasmodium falciparum whole-cell high-throughput screening campaign. Hits displayed activity against multiple stages of the parasite lifecycle, which together with a novel sp3-rich scaffold provided an attractive starting point for a hit-to-lead medicinal chemistry optimization and biological profiling program. Structure-activity-relationship studies led to the identification of compounds that showed low nanomolar asexual blood-stage activity (<50 nM) together with strong gametocyte sterilizing properties that translated to transmission-blocking activity in the standard membrane feeding assay. Mechanistic studies through resistance selection with one of the analogues followed by whole-genome sequencing implicated the P. falciparum cyclic amine resistance locus in the mode of resistance.